Europe Release: Key Facts on Weight Loss Pills

The European Commission has approved the use of Wegovy (Wegovy) in tablet form for obesity treatment. This marks the first oral medication containing semaglutide, a compound that mimics the hormone glucagon-like peptide-1 (GLP-1). The medication aims to suppress appetite and increase feelings of fullness. Studies have shown that continuous use of Wegovy tablets can lead to a weight loss ranging from 14% to 19% over a period of 64 to 72 weeks. The tablets are taken daily on an empty stomach, accompanied by precise instructions to ensure their effectiveness. They are considered a preferred option for adults suffering from obesity, especially those with a body mass index (BMI) of 30 or higher, or 27 with comorbidities such as high blood pressure or diabetes. Research indicates that the tablets provide comparable efficacy to injections in terms of weight reduction, with similar side effects including nausea and diarrhea. Overall, tablets are a less rejection-prone alternative for individuals who prefer to avoid injections.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل